Phenotyping, Etiological Factors, and Biomarkers: Toward Precision Medicine in Autism Spectrum Disorders
Open accessThe DOI matches its Crossref record; 186 of the 186 references it cites were found in a registry or an index.
Abstract
Despite the progress made in understanding the biology of autism spectrum disorder (ASD), effective biological interventions for the core symptoms remain elusive. Because of the etiological heterogeneity of ASD, identification of a “one-size-fits-all” treatment approach will likely continue to be challenging. A meeting was convened at the University of Missouri and the Thompson Center to discuss strategies for stratifying patients with ASD for the purpose of moving toward precision medicine. The “white paper” presented here articulates the challenges involved and provides suggestions for future solutions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Lord, C., Rutter, M., & Le Couteur, A. (1994) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02172145 · Cited by 9,065
Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
(2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113989 · Cited by 6,762
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
Behavioral treatment and normal educational and intellectual functioning in young autistic children.
Lovaas, O. I. (1987) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.55.1.3 · Cited by 3,288
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2011) · The Lancet · doi:10.1016/s0140-6736(11)60993-8 · Cited by 3,075
Research works printed but not linked: 9
- Veenstra-VanderWeele J Sikich L Melmed R Randomized, controlled, phase 2 trial of STX209 for social function in ASD. Int Meet Autism Res (IMFAR). 2013; 13: 102.001.
- Rojas DC Steinmetz S Hepburn SL Auditory gamma-band power is related to GABA concentration in autism. Int Meet Autism Res. 2014; 14: 166.001.
- Hecht P Jasarevic E Matsui F Combined effects of prenatal stress and maternal genotype on interneuron development. Soc Neurosci Abstr. 2014; 44: 518.30.
- Raghavan R Riley A Caruso DM Maternal plasma folate, vitamin B12 levels, and multivitamin supplement during pregnancy and risk for autism spectrum disorders in the Boston Birth Cohort. Int Meet Autism Res Abstr. 2016; 16: 149.004.
- Soorya L Youngkin S Lee SJ A double-blind, placebo-controlled trial of memantine vs. placebo in children with autism targeting neurocognitive outcomes. Int Meet Autism Res Abstr. 2016; 16: 190.003.
- Veenstra-VanderWeele J Pathways to new treatments for autism spectrum disorder (keynote address). Int Meet Autism Res. 2015; 15: 164.
- Matsui F Hecht E Jasarevic E Effect of docosahexaenoic acid (DHA) on a gene/prenatal stress autistic mouse model. Soc Neurosci Abstr. 2014; 44: 518.15.
- Murphy D Why are there so few effective treatments of autism—and can translational neuroscience help? (keynote address). Int Meet Autism Res. 2014; 14: 100.
- Anagnostou E Lerch JP Scherer SW Province of Ontario neurodevelopmental disorders network: integrated discovery from genes to treatment. Int Meet Autism Res. 2015; 15: 125.199.
Cited by
Autism genetics: opportunities and challenges for clinical translation
Vorstman, J. A. S., Parr, J. R., Moreno-De-Luca, D., Anney, R. J. L., Nurnberger Jr, J. I., & Hallmayer, J. F. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.4 · Cited by 463
“Large consortia of ASD clinics and centres will be required to generate data sets based on an agreed set of diagnostic criteria 109 .”
Tackling healthcare access barriers for individuals with autism from diagnosis to adulthood
Malik-Soni, N., Shaker, A., Luck, H., Mullin, A. E., Wiley, R. E., Lewis, M. E. S., Fuentes, J., & Frazier, T. W. (2022) · Pediatric Research · doi:10.1038/s41390-021-01465-y · Cited by 309
Clemente-Suárez, V., Redondo-Flórez, L., Beltrán-Velasco, A., Ramos-Campo, D., Belinchón-deMiguel, P., Martinez-Guardado, I., Dalamitros, A., Yáñez-Sepúlveda, R., Martín-Rodríguez, A., & Tornero-Aguilera, J. (2023) · Biomedicines · doi:10.3390/biomedicines11092488 · Cited by 219
Emerging biomarkers in autism spectrum disorder: a systematic review
Frye, R. E., Vassall, S., Kaur, G., Lewis, C., Karim, M., & Rossignol, D. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.11.53 · Cited by 206
Immune Dysregulation in Autism Spectrum Disorder: What Do We Know about It?
Robinson-Agramonte, M. D. L. A., Noris García, E., Fraga Guerra, J., Vega Hurtado, Y., Antonucci, N., Semprún-Hernández, N., Schultz, S., & Siniscalco, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063033 · Cited by 176
Metadata
- Authors
- Beversdorf, D. Q., & MISSOURI AUTISM SUMMIT CONSORTIUM*
- Affiliations
- University of Missouri Health System (US)
- Corresponding author
- Beversdorf, David Q.
- ORCID
- Beversdorf, David Q.
- Venue
- Journal of Developmental & Behavioral Pediatrics
- Published
- 2016-10
- Volume
- 37
- Issue
- 8
- Pages
- 659-673
- ISSN
- 0196-206X (ISSN-L)
- PMC
- PMC5102276
- OpenAlex
- W2524440579
- Cited by
- 74
- References
- 186
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 5 · 2023: 13 · 2022: 8 · 2021: 6 · 2020: 10 · 2019: 8 · 2018: 12 · 2017: 5
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Developmental & Behavioral Pediatrics (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Autism Speaks
- Simons Foundation
- University of Southern California
- San Diego State University
- University of Missouri
- School of Medicine, Boston University
- University of Louisville
- Harvard T.H. Chan School of Public Health
- University of Missouri-Kansas City
- Children's Mercy Hospital
- University of California, Irvine
- School of Medicine, University of Missouri
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Health Sciences › Medicine › Psychiatry and Mental health › Child Nutrition and Feeding Issues
- Keywords
- autism spectrum disorder, precision medicine, patient stratification, phenotyping, etiology, biomarkers, treatment effect heterogeneity, biological interventions
- MeSH terms
- Autism Spectrum Disorder, Congresses as Topic, Humans, Phenotype, Biomarkers, Practice Guidelines as Topic, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phenotyping, Etiological Factors, and Biomarkers: Toward Precision Medicine in Autism Spectrum Disorders. https://app.cochat.ai/papers/10.1097/dbp.0000000000000351
- The paper
- Beversdorf, D. Q., & MISSOURI AUTISM SUMMIT CONSORTIUM*. (2016). Phenotyping, Etiological Factors, and Biomarkers: Toward Precision Medicine in Autism Spectrum Disorders. Journal of Developmental & Behavioral Pediatrics. https://doi.org/10.1097/dbp.0000000000000351
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.